ASCO Guidelines Bundle

Included Guidelines:

• Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
• Adjuvant Therapy for Stage III Colon Cancer
• Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
• Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer – Brain Metastases
• Antiemetics
• Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression
• Appropriate Systemic Therapy Dosing for Obese Adult Patients with Cancer
• Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy
• Axilla Management in Early-Stage Breast Cancer
• Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
• Biomarkers for Systemic Therapy in Metastatic Breast Cancer
• Bone-Modifying Agents in Metastatic Breast Cancer
• Bone-Modifying Agents in Multiple Myeloma
• Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents
• Cardiac Dysfunction – Prevention and Monitoring in Cancer Survivors
• Cervical Cancer Prevention
• Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma
• Chemotherapy-Naïve Castration-Resistant Prostate Cancer
• Chronic Pain in Survivors of Adult Cancers
• Clear Cell Renal Cell Carcinoma
• Colorectal Cancer Biomarkers
• Colorectal Cancer Early Detection
• Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck
• Diffuse Astrocytic and Oligodendroglial Tumors in Adults
• Early-Stage Breast Cancer
• Estrogen and Progesterone Receptor Testing in Breast Cancer
• Exercise, Diet, and Weight Management During Cancer Treatment
• Fertility Preservation
• Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer
• Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy
• HER2 Testing in Breast Cancer
• Hormone Receptor–Positive Breast Cancer Adjuvant Endocrine Therapy
• HR-Positive, HER2-Negative Metastatic Breast Cancer
• Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy
• Immune-related Adverse Events — CAR T-Cell Therapy
• Initial Management of Noncastrate Advance, Recurrent, or Metastatic Prostate Cancer
• Integrative Medicine for Pain Management in Oncology
• Invasive Cervical Cancer
• Laryngeal Cancer
• Late-Stage Colorectal Cancer
• Lung Cancer Surveillance After Definitive Curative-Intent Therapy
• Malignant Pleural Mesothelioma
• Management of Cancer Cachexia
• Management of Dyspnea in Advanced Cancer
• Management of Hereditary Breast Cancer
• Management of Male Breast Cancer
• Management of Osteoporosis
• Management of Salivary Gland Malignancy
• Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
• Medication-Related Osteonecrosis of the Jaw
• Metastatic Colorectal Cancer
• Metastatic HER2-Negative Breast Cancer – Chemo- and Targeted Therapy
• Metastatic Pancreatic Cancer
• Molecular Biomarkers in Localized Prostate Cancer
• Multiple Myeloma
• Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer
• Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
• Non-Small Cell Lung Cancer — Adjuvant Therapy for Completely Resected Stages I-IIIA
• Optimum Imaging Strategies for Advanced Prostate Cancer
• Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy
• Ovarian Masses and Treatment of Epithelial Ovarian Cancer
• Palliative Care in the Global Setting
• Pancreatic Cancer – Evaluating Susceptibility
• PARP Inhibitors in the Management of Ovarian Cancer
• Platelet Transfusion
• Potentially Curable Pancreatic Adenocarcinoma
• Prevention And Management Of Chemotherapy-Induced Peripheral Neuropathy In Survivors Of Adult Cancers
• Salivary Gland Hypofunction and/or Xerostomia
• Secondary Prevention of Cervical Cancer
• Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer
• Small Renal Masses
• Somatic Genomic Testing for Metastatic or Advanced Cancer
• Stage II Colon Cancer Adjuvant Therapy
• Stage III Non-Small Cell Lung Cancer
• Stage IV Non-Small Cell Lung Cancer without Driver Alterations
• Systemic Therapy for Advanced Hepatocellular Carcinoma
• Systemic Therapy for Melanoma
• Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations
• Treatment for Brain Metastases
• Treatment of Early-Stage Colorectal Cancer
• Treatment of Locally Advanced Esophageal Carcinoma
• Treatment of Metastatic Carcinoma and Myeloma of the Femur
• Use of Endocrine Therapy for Breast Cancer Risk Reduction
• Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer
• White Blood Cell Growth Factors